Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 19 Nov 2026
₹91.58
Change
+1.79 (1.99%)
Open
₹91.58
Prev. Close
₹89.79
Day High
₹91.58
Day Low
₹91.58
Volume Analysis
Traded
28,504
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Trading within 3% of its 52-week high (₹89.8)
- •Promoter holding is rising
Weaknesses (3)
- •Low return on equity (-10.2%)
- •Below-average fundamentals quality score (45/100)
- •Low operating margin (2.2%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 |
| Fibonacci | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 |
| Camarilla | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 | ₹91.58 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+19.57%
1 Week
+10.38%
1 Month
+8.61%
3 Months
+24.4%
6 Months
+49.13%
1 Year
+14.22%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹31.56
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
-4.65%
Net margin -3.45% × asset turnover 0.71x × equity multiplier 1.9x
Company Overview
Sector
Healthcare
Market Cap
₹328 Cr
ROE
-10.2%
Book Value
₹26.5
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Lyka Labs Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 45/100. The strongest factor is Momentum (100/100), while Liquidity (0/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹89.8); promoter holding is rising; low return on equity (-10.2%); below-average fundamentals quality score (45/100).
TopFund Score — Fundamentals Quality
45/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company's working capital requirements have reduced from 32.4 days to 22.7 days
- −Stock is trading at 3.39 times its book value
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 8.29% over past five years.
- −Company has a low return on equity of -2.04% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
NSE fined Lyka Labs ₹1.62 lakh plus GST for delayed FY2025-26 annual report submission.
NSE imposed ₹1.62 lakh plus GST fine for delayed FY2025-26 annual report submission.
Lyka Labs approved Q2 FY2026 results, postal ballot, and Neeraj Golas’ 3-year independent director reappointment.
Board approved Q2 FY2026-27 standalone and consolidated results; reappointed Neeraj Golas as independent director from 16 January 2027, subject to shareholder approval.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 28 | 33 | 28 | 30 | 41 | 34 | 33 | 33 | 37 | 31 | 28 | 42 | 44 |
| Expenses + | 24 | 26 | 26 | 26 | 36 | 29 | 29 | 29 | 39 | 29 | 34 | 38 | 41 |
| Operating Profit | 4 | 7 | 2 | 4 | 5 | 5 | 4 | 4 | -3 | 2 | -6 | 5 | 4 |
| OPM % | 14.9% | 21.1% | 7.27% | 12.32% | 12.03% | 15.36% | 12.2% | 11.14% | -6.93% | 5.37% | -23.01% | 10.75% | 7.96% |
| Other Income + | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -1 | 3 | -2 | 2 | 3 | 4 | 3 | 1 | -4 | 0 | -9 | 2 | 1 |
| Tax % | -22.78% | 38.6% | 28.22% | 30.65% | 28.36% | 24.3% | 32.89% | 26.67% | -26.65% | -6.25% | -6.06% | -5.13% | -18.69% |
| Net Profit + | 0 | 2 | -2 | 1 | 2 | 3 | 2 | 1 | -3 | 0 | -8 | 2 | 1 |
| EPS in Rs | 0 | 1 | -1 | 0 | 1 | 1 | 1 | 0 | -1 | 0 | -2 | 1 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 10 | 83 | 25 | 32 | 47 | 4 | 20 | 10 | -11 | -9 | -16 | 28 | 21 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | 128 | 145 |
| Expenses + | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | 132 | 142 |
| Operating Profit | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 | -3 | 3 |
| OPM % | 17.0% | 16.0% | 21.0% | -6.0% | -2.7% | -6.0% | 23.0% | 52.0% | 18.0% | 14.0% | 13.0% | -2.7% | 2.2% |
| Other Income + | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 | 4 | 3 |
| Interest | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 | 3 | 4 |
| Depreciation | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 | 8 | 8 |
| Profit before tax | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 | -12 | -6 |
| Tax % | 31.0% | -5.0% | -19.0% | -5.0% | -59.0% | 1.0% | -29.0% | 35.0% | 0.0% | 182.0% | 29.0% | -11.0% | — |
| Net Profit + | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | -10 | -5 |
| EPS in Rs | -2 | 2 | -3 | -6 | -2 | -21 | -4 | 14 | -4 | -1 | 2 | -3 | -1 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | 40 | 10 | -16 | -46 | 18 | -13 | 40 | 125 | -52 | 19 | 25 | -7 | 6 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 20 | 22 | 16 | 21 | 15 | -43 | -54 | -15 | 15 | 35 | 69 | 57 | 60 |
| Borrowings + | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 39 | 49 | 44 |
| Other Liabilities + | 100 | 77 | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 32 | 33 | 42 |
| Total Liabilities | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 175 | 182 |
| Fixed Assets + | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 85 | 87 | 89 |
| CWIP | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 1 | 2 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 90 | 86 | 91 |
| Total Assets | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 | 175 | 182 |
| Equity Capital | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 | 36 | 36 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 27 | 12 | 31 | 11 | 27 | 5 | 9 | 79 | 9 | 2 | 2 | 5 |
| Cash from Investing Activity + | 37 | 17 | -13 | -3 | -4 | 0 | 0 | -6 | 7 | -9 | -12 | -9 |
| Cash from Financing Activity + | -60 | -30 | -19 | -10 | -23 | 3 | -12 | -63 | -22 | 2 | 5 | 4 |
| Net Cash Flow | 4 | -1 | 0 | -3 | -1 | 9 | -3 | 10 | -5 | -6 | -5 | 0 |
| Free Cash Flow | 55 | 28 | 18 | 7 | 23 | 4 | 8 | 72 | 15 | -7 | -10 | -6 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 97 | 60 | 143 | -318 | -1,462 | -131 | 49 | 79 | 52 | 21 | 28 | -159 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 44.41% | 44.21% | 40.99% | 41.08% | 41.07% | 40.93% | 41.02% | 40.99% | 40.99% | 40.89% | 40.73% | 40.73% |
| Promoters | 54.81% | 54.81% | 58.11% | 58.11% | 58.11% | 58.16% | 58.16% | 58.16% | 58.16% | 58.16% | 58.45% | 58.45% |
| FII | 0.17% | 0.17% | 0.15% | 0.15% | 0.15% | 0.24% | 0.16% | 0.17% | 0.17% | 0.29% | 0.17% | 0.15% |
| DII | 0.62% | 0.81% | 0.75% | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% | 0.66% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Lyka Labs Ltd. (this stock) | 328 | — | 3.39 | -10.2% |
| Qms Medical Allied S Ltd | 336 | 31.3 | 3.23 | 10.4% |
| Ambalal Sarabhai Ent L | 304 | 19.6 | 1.86 | 12.4% |
| Nureca Limited | 293 | 61.4 | 1.56 | 1.12% |
| Medicamen Biotech Limited | 407 | 35.2 | 1.39 | 3.95% |
| Brooks Lab Limited | 203 | 58.7 | 1.08 | 22.0% |
| Bilcare Ltd. | 202 | 5.55 | 1.13 | 1.39% |
Which Mutual Funds Hold Lyka Labs Ltd.?
Frequently Asked Questions about Lyka Labs Ltd.
Lyka Labs Ltd. (LYKALABS) closed at ₹91.58 on NSE on 19 November 2026, up 1.79 (1.99%) from the previous close.
Lyka Labs Ltd. trades on the NSE (National Stock Exchange of India) under the symbol LYKALABS.
Lyka Labs Ltd. has a dividend yield of 0.0%.
Lyka Labs Ltd.'s 52-week high is ₹89.8 and its 52-week low is ₹44.1.
Lyka Labs Ltd. has a market capitalisation of ₹328 crore.
Lyka Labs Ltd. has a TopFund Quality Score of 45/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Lyka Labs Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.